Phase 2 Study of Vilobelimab Fully Enrolled in Europe

Phase 2 Study of Vilobelimab Fully Enrolled in Europe

283149

Phase 2 Study of Vilobelimab Fully Enrolled in Europe

InflaRx has completed enrollment in its Phase 2 trial evaluating vilobelimab (IFX-1) for people with ANCA-associated vasculitis (AAV) in Europe. “We are pleased to have met our enrollment goal in the vilobelimab European phase II trial in AAV,” Korinna Pilz, MD, global head of clinical research and development of InflaRx, said in a press release. Vilobelimab is a first-in-class antibody designed to target and block the activity of the complement activation C5a protein. A component…

You must be logged in to read/download the full post.